Comparative Pharmacology
Head-to-head clinical analysis: SIMPESSE versus TRI LO MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SIMPESSE versus TRI LO MILI.
SIMPESSE vs TRI-LO-MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Simpesse is a combination estrogen-progestin oral contraceptive that suppresses gonadotropin release, primarily inhibiting ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis. Additionally, it alters cervical mucus viscosity and endometrial receptivity.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; norgestimate binds to progesterone receptors, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
Oral: 10 mg once daily, taken at least 1 hour before a meal.
One tablet orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Terminal elimination half-life is 24 hours (range 20-28 hours), supporting once-daily dosing.
Terminal elimination half-life: 20-24 hours; allows once-daily dosing for contraceptive efficacy.
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; hepatic metabolism produces inactive metabolites that are excreted renally (20-30%) and fecally (<10%).
Renal: approximately 50% as metabolites; biliary/fecal: approximately 40% as metabolites; 10% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive